Phase 1 vs Phase 2 — Hematology Deal Valuation Comparison

Phase 1 Median Upfront

$200M

Total: $1.6B

Phase 2 Median Upfront

$604M

Total: $3.0B

Stage Premium

85%

Phase 2 premium over Phase 1

Phase 1 Royalties

5.3%-11.7%

vs Phase 2: 8.5%-16%

Model Your Deal

Market Analysis

The Phase 1 to Phase 2 transition in hematology represents a significant value inflection point. Phase 2 deals carry a median total deal value of $3.0B compared to $1.6B at Phase 1, a 85% premium reflecting clinical de-risking. Upfront payments increase from $200M to $604M.

Deal structures shift as assets advance. Phase 1 deals allocate 12% to upfront and 88% to milestones, while Phase 2 deals shift to 20%/80%. Development milestones move from $481M to $500M, and royalty rates evolve from 5.3%-11.7% to 8.5%-16%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 1 to Phase 2 in hematology?

Phase 2 hematology deals command a 85% premium over Phase 1 in total deal value ($3.0B vs $1.6B). Upfronts increase from $200M to $604M, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 1 and Phase 2 in hematology?

Phase 1 deals are more milestone-weighted (88% milestones), reflecting higher clinical risk. Phase 2 deals shift toward higher upfront allocations (20% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a hematology asset?

The optimal licensing window depends on strategic priorities. Phase 1 assets offer lower entry cost for licensees, while Phase 2 assets provide more certainty. The 85% premium from Phase 1 to Phase 2 reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough